TRX — Tissue Regenix Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- £5.18m
- £12.15m
- $28.65m
Annual cashflow statement for Tissue Regenix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.1 | -5.14 | -2.83 | -1.67 | -0.564 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 10.2 | 1.54 | 1.01 | 1.97 | 1.6 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.15 | -0.468 | -0.616 | -0.239 | -3.72 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -6.05 | -2.98 | -1.29 | 1.04 | -1.64 |
| Capital Expenditures | -1.87 | -2.05 | -1.09 | -0.863 | -4.07 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.003 | 0.003 | 0.008 | 0.026 | 0.011 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.86 | -2.04 | -1.08 | -0.837 | -4.06 |
| Financing Cash Flow Items | -1.7 | -0.692 | -0.741 | -1.21 | -0.904 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.7 | -0.192 | 0.91 | -1.51 | 3.28 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 9.85 | -5.26 | -1.76 | -1.3 | -2.44 |